Global Health Investment Fund (GHIF)

Monod Bio is a life sciences company developing biosensors for protein and other analyte detection. Its biosensor platform combines binding, transduction, and amplification to detect a range of target molecules. It utilizes recent advances in computational protein engineering to create highly modular bio-sensing nano switches that stimulate rapid, sensitive, and inexpensive analytical assays. Monod Bio was founded in 2021 and is headquartered in Seattle, Washington.

Endpoint Health is a precision immunology company that is breaking the efficacy barrier of traditional pharma's “one-size-fits-all” drug development strategy by developing precision therapies with outsized efficacy potential in autoimmune and inflammatory conditions. They’re accomplishing this by leveraging OMNAI, their proprietary AI-powered patient discovery platform, to identify and match high-potential therapies to the patients most likely to respond.

Eyenuk is a medtech company that develops an artificial intelligence screening tool for risk assessment and disease surveillance. The company's first product, the EyeArt AI Eye Screening System, is the most extensively validated AI technology for the autonomous detection of diabetic retinopathy. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life-and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease. The company was founded in 2010 and is based in Los Angeles, California.

Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Their single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. They are devoted to improving the lives of women around the world.

Plethy is an InsurTech & HealthTech company delivering patient outcomes and financial ROI for Self-Insured Enterprises, Insurance Carriers, and Health Systems. Plethy’s bio-psycho-social program makes it easy for patients to manage their musculoskeletal care at home. The solution delivers AI driven patient recovery and claims closure through predictive analytics.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Alydia Health is a medical device company working toward a solution to postpartum hemorrhage (PPH), the number one cause of maternal death. Their single-minded focus is to improve radically the treatment path for postpartum hemorrhage from the traumatic, life-altering condition that it is today. They are devoted to improving the lives of women around the world.

Univercells is a One-stop-shop for high-density low-cost biomanufacturing "end-to-end" solutions, with innovative engineering able to decrease the needs for investments of over 75% and the cost of goods of up to 90%. Univercells' technologies, aimed at low cost manufacturing of antibodies/proteins/vaccines, is based on single-use technologies, and chaining of three manufacturing steps into simulated continuous mode : cell culture under perfusion, clarification and capture.

Themis Bioscience is a start-up biotechnology company developing vaccines to prevent infectious diseases. The company’s development focus is primarily concentrated on emerging and specialist indications, advancing promising vaccines from preclinical to late-stage clinical development phases. We aim to exploit the increasing licensing and acquisition trend to generate value by developing and partnering our technology programs and vaccine candidates. It is our mission to establish Themis as a first class biotech development boutique and to become a preferred licensing partner for leading biotech and pharmaceutical companies.

Iantech has developed advanced micro-­interventional technology for cataract surgery. After 50 years of conventional phacoemulsification, Iantech introduces a micro-­interventional technique designed to deliver energy-­free endocapsular lens fragmentation, giving surgeons control, efficiency and new opportunities to improve their surgical technique. At Iantech, They are working to invent new surgical approaches which can reduce the global footprint of cataract blindness. Using smart, efficient and adaptable micro-­interventional technology, Their team is building a new surgical platform to catalyze global outreach efforts as we fight the 25M blindness epidemic in the world

PATH is an international nonprofit organization that transforms global health through innovation. They take an entrepreneurial approach to developing and delivering high-impact, low-cost solutions, from lifesaving vaccines and devices to collaborative programs with communities. Through our work in more than 70 countries, PATH and our partners empower people to achieve their full potential.

Atomo Diagnostics was established to capitalize on a core belief that health care products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants. Having identified the usability challenges and in-field limitations of existing RDT products, Atomo worked closely with healthcare workers and consumers in a range of settings and determined that by integrating all the test components into a streamlined, end-to-end solution it could significantly improve safety and accuracy and reduce user error rates. This focus on usability and how end users interact with the RDT is one of the key aspects that sets Atomo apart from its competition in the POCT market. Its unique design and patented features mean that AtomoRapid™ addresses and eliminates the vast majority of user errors identified as impacting the performance of standard RDTs in the field. AtomoRapid™ makes it easy to convert proven diagnostic technologies into user-friendly products that deliver unmatched customer satisfaction and in-field performance. These products are successful due to their ability to materially improve usability, convenience, and reliability for both professional and home users. It is this unswerving focus on exceeding user expectations that the management team has applied to the diagnostic market; a market that has to date seen little user-centric innovation. Atomo Diagnostics is headquartered in Sydney, Australia, with corporate offices located in South Africa the UK. The company is led by an executive team with a track record of success commercializing disruptive healthcare products, and the company has assembled an experienced and committed international management team and Board and advisors.

Access BIO is a consulting group focused on the development of drug, biologic, and medical device products. The company’s product portfolio includes rapid diagnostic tests, molecular diagnostics, biosensors, and more. Access BIO was founded in 2001 and is based in Somerset, New Jersey.

Atomo Diagnostics was established to capitalize on a core belief that health care products offering significantly improved levels of convenience, simplicity and user experience are disproportionately disruptive and have the potential to be very successful commercial market entrants. Having identified the usability challenges and in-field limitations of existing RDT products, Atomo worked closely with healthcare workers and consumers in a range of settings and determined that by integrating all the test components into a streamlined, end-to-end solution it could significantly improve safety and accuracy and reduce user error rates. This focus on usability and how end users interact with the RDT is one of the key aspects that sets Atomo apart from its competition in the POCT market. Its unique design and patented features mean that AtomoRapid™ addresses and eliminates the vast majority of user errors identified as impacting the performance of standard RDTs in the field. AtomoRapid™ makes it easy to convert proven diagnostic technologies into user-friendly products that deliver unmatched customer satisfaction and in-field performance. These products are successful due to their ability to materially improve usability, convenience, and reliability for both professional and home users. It is this unswerving focus on exceeding user expectations that the management team has applied to the diagnostic market; a market that has to date seen little user-centric innovation. Atomo Diagnostics is headquartered in Sydney, Australia, with corporate offices located in South Africa the UK. The company is led by an executive team with a track record of success commercializing disruptive healthcare products, and the company has assembled an experienced and committed international management team and Board and advisors.

BD is a medical technology company advancing health by improving medical discovery, diagnostics, and the delivery of care. BD leads in patient and healthcare worker safety and the technologies that enable medical research and clinical laboratories.

genedrive plc is a commercial stage medical devices company, targeting opportunities in infectious diseases, biosurveillance, and animal applications. Our Genedrive® system is positioned to offer lower cost, easy to use, point of need or clinic-based molecular diagnostic tests via a 'razor/razor blade'​ business model across an increasing range of applications. Genedrive® is rapidly reconfigurable for specific assays and is suitable for use outside a traditional hospital setting. The system analyses nucleic acids from fresh or stored samples to provide rapid diagnosis and decision making.

EuBiologics Co., Ltd. is a South Korean biopharmaceutical company focused on developing and supplying vaccines aimed at addressing epidemics and antibiotic resistance. The company offers several products, including Euvchol, an oral cholera prevention vaccine, and CRM197, a diphtheria toxin mutant vaccine. In addition to its vaccine portfolio, EuBiologics provides a range of customized services related to biopharmaceutical development, encompassing mammalian and microbial cell-derived products. These services include cell line development, GMP production, validation, and regulatory support. The company also specializes in manufacturing recombinant biological products and antibody therapeutics, along with offering process, formulation, and analytical method development. Furthermore, EuBiologics provides contract testing services, which cover lot release, stability, raw material, and method validation testing. Founded in 2010 and headquartered in Seoul, EuBiologics aims to contribute to global public health through its innovative solutions.